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Summary
We recently reported that SHIP restrains LPS-induced
classical (M1) activation of in vitro differentiated,
bone marrow-derived macrophages (BMMs) and
that SHIP upregulation is essential for endotoxin tol-
erance. Herein, we show that in vivo differentiated
SHIP−/− peritoneal (PMs) and alveolar (AMs) mac-
rophages, unlike their wild-type counterparts, are pro-
foundly M2 skewed (alternatively activated), possess-
ing constitutively high arginase I (ArgI) and Ym1
levels and impaired LPS-induced NO production.
Consistent with this, SHIP−/− mice display M2-medi-
ated lung pathology and enhanced tumor implant
growth. Interestingly, BMMs from SHIP−/− mice do
not display this M2 phenotype unless exposed to
TGF within normal mouse plasma (MP) during in vi-
tro differentiation. Our results suggest that SHIP func-
tions in vivo to repress M2 skewing and that macro-
phage polarization can occur during differentiation in
response to TGF if progenitors have elevated PIP3.
Introduction
Macrophages (MΦs) orchestrate both the initiation and
resolution phases of inflammation. The initial inflamma-
tory response is carried out by classically activated
(M1) MΦs, which eradicate invading microorganisms
and tumor cells and promote type I immune responses,
while the resolution phase is carried out by alternatively
activated (M2) MΦs, which are hyporesponsive to pro-
inflammatory stimuli and are involved in debris scav-
enging, angiogenesis, tissue remodeling, wound heal-
ing, and the promotion of type II immunity (Gordon,
2003; Mosser, 2003; Stein et al., 1992). Interestingly,
MΦs within tumors (tumor-associated macrophages,
TAMs) or from patients with severe or chronic inflam-
mation resemble M2 MΦs (Gordon, 2003). In the case
of severe/chronic inflammation, this is thought to be an
adaptation to avoid damage to the host (Dal Pizzol,
2004; Takahashi et al., 2004). However, in the case of*Correspondence: gkrystal@bccrc.ca
4 Present address: StemCell Technologies, Vancouver, British Co-
lumbia V5Z 4J7, Canada.cancer, M2 skewing enables tumors to exploit the heal-
ing properties of this subclass of MΦs for tumor growth
and immune system evasion (Rodriguez et al., 2004).
Despite these observations and the great therapeutic
potential of harnessing MΦ polarization, the mecha-
nisms underlying MΦ programming have yet to be fully
elucidated. Moreover, it is unresolved whether M1 and
M2 MΦs represent distinct, defined lineages, or whether
mature MΦ phenotypes are plastic and adaptable to
ever-changing environmental cues (Mills et al., 2000;
Stout and Suttles, 2004).
We recently demonstrated that the Src homology
2-containing inositol-5#-phosphatase, SHIP, a potent
negative regulator of the phosphatidylinositol 3-kinase
(PI3K) pathway in hematopoietic cells, restrains lipo-
polysaccharide (LPS)-induced proinflammatory cyto-
kine and nitric oxide (NO) production from in vitro de-
rived bone marrow macrophages (BMMΦs) (Sly et al.,
2004). We also showed that LPS stimulates a 10-fold
increase in SHIP protein levels and that this elevation
in SHIP plays a critical role in dampening down the ef-
fects of a second exposure to LPS (i.e., its upregulation
is essential for endotoxin tolerance [Sly et al., 2004]).
To extend the findings that we obtained with in vitro
generated BMMΦs, we compared the effects of LPS on
primary peritoneal (PMΦs) and alveolar (AMΦs) macro-
phages from SHIP+/+ and −/− mice. In contrast to our
results with in vitro derived BMMΦs, we report herein
that SHIP−/− PMΦs and AMΦs produce far less NO than
their wild-type counterparts because of constitutively
elevated levels of arginase I (ArgI), which competes
with inducible nitric oxide synthase (iNOS) for the com-
mon substrate, L-arginine. In addition, we find that in
vivo differentiated SHIP−/− MΦs display other features
characteristic of an M2 phenotype. However, this M2
skewing is not observed with in vitro derived SHIP−/−
BMMΦs unless TGFβ1-containing mouse plasma (MP)
is added early to standard in vitro differentiation cul-
tures. Taken together, our results suggest that SHIP−/−
MΦs are M2 skewed because of elevated intracellular
levels of PIP3 as well as exposure to extracellular fac-
tors during a critical stage in their development.
Results
LPS-Stimulated SHIP−/− PMs Secrete Low Levels
of NO but Can Be Rescued by Exogenous
L-Arginine
In preliminary studies with in vitro generated BMMΦs,
we found that LPS stimulated more NO secretion from
SHIP−/− than +/+ BMMΦs and that the PI3K inhibitor,
LY294002, markedly inhibited this NO production from
both cell types (Figure 1A, left). Since we recently
showed that LPS-treated SHIP−/− BMMΦs display
higher PI3K pathway activation than wild-type BMMΦs
(as assessed by higher pAkt levels [Sly et al., 2004]),
these results are consistent with the PI3K pathway be-
ing a positive regulator of LPS-induced NO production.
However, there was no significant difference in the
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362Figure 1. LPS-Stimulated SHIP−/− PMΦs, Unlike BMMΦs, Are Deficient in NO Production due to Limiting L-Arginine
(A) SHIP+/+ and −/− BMMΦs (106 cells/ml) were treated with LPS ± IFNγ for 24 hr ± prior (30 min) addition of DMSO vehicle or LY294002 (left)
or for the indicated times with 100 ng/ml LPS + 20 U/ml IFNγ (right), and the conditioned media were analyzed for nitrite levels.
(B) SHIP+/+ and −/− resting (left) or thioglycollate-elicited (middle) PMΦs were treated ± LPS and IFNγ for 24 hr (left) or LPS (100 ng/ml) + IFNγ
(20 U/ml) (middle) and NO production measured. Total cell lysates (TCLs) were also prepared from equal numbers of these PMΦs and
subjected to Western analysis for iNOS (right).
(C) SHIP+/+ (squares) and −/− (triangles) PMΦs were treated with 100 ng/ml LPS + 100 U/ml IFNγ for the indicated times, and NO production
was measured with (open symbols) or without (closed symbols) 30 min prior addition of 2 mM L-arginine.
(D) SHIP+/+ and −/− PMΦs and BMMΦs were treated for 48 hr with LPS + IFNγ (as in [C]) ± 2 mM L-arginine, and NO production was measured
and expressed as % increase in NO of L-arginine supplemented/nonsupplemented controls. Data points in all panels are the means ± SEM
of at least triplicate determinations, except for duplicate determinations in (D). Significant difference between SHIP+/+ and SHIP−/−: *p < 0.05,
**p < 0.01, ***p < 0.001, using unpaired two-tailed Student’s t test. Similar results were obtained in at least three separate experiments.amount of NO produced from SHIP+/+ and −/− BMMΦs
in response to LPS + IFNγ (Figure 1A, left and right).
This suggests, perhaps, that the primary effect of the
PI3K pathway in LPS-induced BMMΦs is to increase
the production of autocrine-acting IFNβ, since addition
of exogenous IFNγ would negate this effect. This is
consistent with previous studies showing that PI3K
positively regulates the translation and/or secretion of
IFNβ (Rhee et al., 2003; Weinstein et al., 2000).
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SUnexpectedly, when we then compared the ability of
n vivo differentiated PMΦs from SHIP+/+ and −/− mice
o produce NO in response to LPS or LPS + IFNγ, we
ound that the SHIP−/− PMΦs produced far less NO (Fig-
re 1B, left and middle). The cells used to generate the
iddle panel of Figure 1B were also subjected to West-
rn analysis to determine if LPS+ IFNγ was less efficient
t upregulating inducible nitric oxide synthase (iNOS) in
HIP−/− PMΦs. As shown in Figure 1B (right), this was
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363not the case. Although further studies revealed that
LPS-induced iNOS levels were sometimes lower and
sometimes higher in LPS-induced SHIP−/− PMΦs, LPS-
induced NO was consistently lower in SHIP−/− PMΦs.
We then asked if the iNOS substrate, L-arginine, was
limiting in SHIP−/− PMΦs by comparing NO production
from LPS + IFNγ-stimulated SHIP+/+ and −/− PMΦs ±
exogenously added 2 mM L-arginine. Of note, the level
of L-arginine in IMDM is approximately 400 M. As
shown in Figures 1C and 1D, the addition of L-arginine
had a negligible effect on NO production from LPS +
IFNγ-stimulated SHIP+/+ PMΦs but dramatically in-
creased NO production from SHIP−/− PMΦs. Notably,
this effect was not observed with in vitro derived SHIP−/−
BMMΦs (Figure 1D).
LPS-Stimulated SHIP−/− PMs and AMs Secrete
Low Levels of NO because of Constitutively
High Arginase Activity
To investigate why SHIP−/− PMΦs had inadequate
stores of L-arginine for NO synthesis, we noted from
the literature that M2 MΦs possess very high levels of
arginase I (ArgI) and this effectively competes with
iNOS for L-arginine, converting it into urea and ornith-
ine, the latter being metabolized to polyamines and
proline to stimulate cell proliferation and collagen for-
mation, respectively (Goerdt and Orfanos, 1999; Gor-
don, 2003; Mills, 2001). We therefore asked if ArgI was
elevated in SHIP−/− PMΦs and found this was indeed
the case. Specifically, while the protein levels of ArgI
increased slightly in wild-type PMΦs with time follow-
ing LPS + IFNγ, they were markedly and constitutively
elevated in SHIP−/− PMΦs (Figure 2A). To determine if
these constitutively elevated ArgI levels in SHIP−/−
PMΦs were responsible for the low LPS-induced NO
production from these cells, we compared the effects
of the arginase inhibitors, L-nor-NOHA and L-nor-
valine, and found that they significantly increased LPS-
induced NO production from SHIP−/− but not +/+ PMΦs
(see Figure S1 in the Supplemental Data available with
this article online).
ArgI expression is restricted primarily to hepatocytes
(where it is expressed in a constitutive fashion to gener-
ate urea as part of the urea cycle) and to MΦs (where
it is expressed in an inducible fashion) (Wu and Morris,
1998). As shown in Figure 2B, ArgI levels (left) and ac-
tivity (right) were also dramatically elevated in SHIP−/−
AMΦs isolated from bronchoalveolar lavage (BAL).
Consistent with this, we found that SHIP−/− produced
less NO than SHIP+/+ AMΦs in response to LPS + IFNγ
(data not shown). However, as shown in Figure 2C,
there was no detectable difference in ArgI levels (left)
or activity (right) in hepatocyte-rich liver homogenates
from SHIP+/+ and −/− mice, suggesting that the differ-
ences were MΦ specific.
Arginase I Levels Are Upregulated
by the PI3K Pathway
To gain some insight into why ArgI levels were elevated
in SHIP−/− PMΦs and AMΦs, we stimulated SHIP+/+
PMΦs with LPS ± LY294002 or wortmannin and found
that these PI3K inhibitors reduced LPS-induced ArgI
levels (Figure 2D). We then transiently transfected SHIP+/+PMΦs with a constitutively active PI3K (p110CAAX) and
found that it caused a modest, dose-dependent in-
crease in both arginase activity and ArgI levels in the
absence of LPS stimulation (Figure 2E). We also sub-
jected SHIP−/− PMΦs to low doses of LY294002 for 48
hr and found that it reduced both arginase activity and
ArgI levels (Figure 2F). These results were consistent
with PI3K being a positive regulator of ArgI and sug-
gested that the increased PIP3 levels in SHIP−/− PMΦs
were responsible for the increased arginase activity. We
then asked if the increased ArgI protein levels in SHIP−/−
PMΦs were due, at least in part, to increased transcrip-
tion and/or stability of ArgI mRNA by carrying out semi-
quantitative RT-PCR of unstimulated SHIP+/+ and −/−
PMΦs. As shown in Figure 2G, higher ArgI mRNA levels
were present in SHIP−/− PMΦs.
Evidence for SHIP−/− M2 M Skewing In Vivo
To gather evidence for M2 MΦ skewing in vivo, we
compared histological sections of lungs from >8-week-
old SHIP+/+ and −/− mice and found considerable con-
solidation and fibrosis in the latter (Figure 3A, compare
panels 1 and 2). This was consistent with M2-MΦ-
induced proliferation (Song et al., 2000) and reminis-
cent of human TH2-skewed asthmatic lungs (Zimmer-
mann et al., 2003). Additionally, SHIP−/− lungs and BAL
fluids (BALF) revealed the presence of large, hexago-
nal, MΦ-associated crystals (Figure 3A, panels 3–6).
Similar crystals have been reported in the lungs of
motheaten viable (MeV) mice, which lack functional
tyrosine phosphatase 1 (SHP1), and have been shown
in these mice to be composed of the chitinase-like
protein, Ym1 (Guo et al., 2000). To determine if MΦs
from SHIP−/− mice also express Ym1, we carried out
semiquantitative RT-PCR with both PMΦs and AMΦs,
and we found that Ym1 mRNA levels were indeed ele-
vated in SHIP−/− MΦs (Figure 3B). To confirm this at the
protein level, in the absence of commercially available
anti-Ym1, we carried out SDS-PAGE with both cell-free
BALF from SHIP+/+ and −/− mice and with purified crys-
tals from the BALF of SHIP−/− mice, and we found a
prominent 45 kDa Coomassie blue band, correspond-
ing to the molecular mass of Ym1 (Guo et al., 2000;
Hung et al., 2002), only in the SHIP−/− fluids and mark-
edly enriched in the crystals from SHIP−/− mice (Figure
3C). Mass spectral analysis of this purified band con-
firmed that it was Ym1 (Table S1). We then generated a
rabbit anti-Ym1 antibody and used it to confirm en-
hanced expression of Ym1 in SHIP−/− AMΦs and BALF
(Figure 3D) and PMΦs (Figure 3E). Cross-reactive
bands of 52, 39, and 30 kDa were also elevated in
SHIP−/− MΦs and BALF (Figure 3E) and may represent
AMCase, chitotriosidase 1, and a breakdown product
of Ym1, respectively (Boot et al., 2001; Nio et al., 2004),
given the peptide antigen used. Of note, our detecting
Ym1 protein in SHIP+/+ AMΦs but not PMΦs is consis-
tent with our RT-PCR results (Figure 3B) and confirms
a previous report showing that Ym1 is present in wild-
type AMΦs (Hung et al., 2002).
Given the presence of M2 MΦs in SHIP−/− mice, we
asked if these mice were more amenable to tumor
growth (Mantovani et al., 2002; Rodriguez et al., 2004)
by subcutaneously injecting M27 Lewis lung carcinoma
Immunity
364Figure 2. LPS-Stimulated SHIP−/− PMΦs and AMΦs Secrete Low Levels of NO due to Constitutively High Arginase Activity
(A) SHIP+/+ and −/− PMΦs (106 cells/ml) were stimulated for the indicated times with 100 ng/ml LPS + 20 U/ml IFNγ and TCLs subjected to
Western analysis for ArgI and IκBα.
(B) Unstimulated AMΦs isolated from SHIP+/+ or −/− BAL fluid by adherence were lysed after overnight incubation and subjected to ArgI and
GAPDH Western analysis (left) or arginase activity assays (right) in which the amount of urea produced from the hydrolysis of L-arginine in 1
hr was normalized to the amount of protein in the lysate (**p < 0.01).
(C) Liver homogenates, prepared from SHIP+/+ and −/− mice in arginase assay lysis buffer, were subjected to ArgI and GAPDH Western
analysis (left) and arginase activity assays (right) as in (B).
(D) SHIP+/+ PMΦs, pretreated for 30 min with wortmannin, LY294002, or DMSO, were treated ± 200 ng/ml LPS for 24 hr. TCLs from equal
numbers of cells were subjected to ArgI and GAPDH Western analysis.
(E and F) SHIP+/+ PMΦs (2 × 106 cells/6 cm plate) (E) were transiently transfected with the indicated amount of p110CAAX using DEAE-
dextran, allowed to recover overnight, or SHIP−/− PMΦs (F) were incubated for 48 hr with the indicated concentration of LY294002, and lysates
prepared for arginase assays (upper panels) or ArgI, Erk1, and Grb2 Western analysis (lower panels).
(G) Total RNA was obtained from SHIP+/+ and −/− PMΦs using Trizol and mRNA levels of ArgI and β-actin determined by semiquantitative
RT-PCR, using specific primers and after titrating optimal cycle numbers. Results are representative of at least two separate experiments.
Bar graphs are the means ± SEM of quadruplicate determinations.
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(A) Panels 1 and 2 are photomicrographs of Mason trichrome stained histological sections of SHIP+/+ (1) and −/− (2) lungs (200×). Panel 3 is
a photomicrograph of an H&E-stained SHIP−/− lung histological section revealing a bronchiolar lumen occluded with MΦ-associated, extracel-
lular, eosinophilic crystals. Panel 4 is an image of tissue culture plate-adherent SHIP−/− AMΦs and MΦ-associated crystals. Panel 5 is a
photomicrograph of H&E-stained SHIP−/− lung showing a hexagonal, eosinophilic crystal almost occluding a lumen, and panel 6 is a similar
MΦ-associated crystal observed in BAL fluid (400× for panels 3–6).
(B) Total RNA was obtained from SHIP+/+ and −/− PMΦs or AMΦs and subjected to Ym1 RT-PCR, by use of specific primers and after titrating
optimal cycle numbers. β-actin was also optimally titrated as a control.
(C) 40 g of total BALF protein from SHIP+/+ and SHIP−/− mice, together with purified crystals obtained from 3 ml of pooled BALF from SHIP−/−
mice by repeated centrifugations through Ficoll-diatrizoate, were boiled for 10 min in SDS-sample buffer and resolved by SDS-PAGE. A 45 kDa
Coomassie-stained protein band enriched in SHIP−/− cell-free BALF that comigrated with purified crystals is indicated by an open arrowhead.
(D) Normalized protein equivalents from SHIP+/+ and −/− AMΦ lysates, BALF, or PMΦs (E) were subjected to Western analysis using antibodies
to Ym1, ArgI, and Grb2.
(F) 6- to 10-week-old SHIP+/+ (filled squares) (n = 11) and −/− (open triangles) (n = 10) mice were subcutaneously injected with 2 × 105 M27
Lewis lung carcinoma cells and tumor volume (mm3) measured over time (left) (**p < 0.01). Each data point is the mean ± SEM of n. Tumors
were also harvested from several mice on day 17, and lysates with equivalent protein levels were subjected to Western analysis for c-fms,
ArgI, and GAPDH (right).cells into SHIP+/+ and −/− mice. As shown in the left
panel of Figure 3F, the tumors grew substantially faster
in the SHIP−/− mice. We also analyzed the tumors fortheir ArgI levels and found they were significantly
higher in SHIP−/− mice (Figure 3F, right). Related to this,
a recent mouse study showed that within subcutane-
Immunity
366Figure 4. Further Characterization of the SHIP−/− MΦ Phenotype and Its Dependence on Mouse Age
(A) PMΦs from 10-week-old SHIP+/+ (black bars) and −/− (gray bars) mice were treated with LPS (100 ng/ml), and the secreted levels of TNFα,
IL-6, CCL3, IL-12, or IL-10 were determined by ELISA. The same cells were treated for 18 hr ± LPS (200 ng/ml), and the amount of latent +
active TGFβ produced was assessed by ELISA. Data shown are the means ± SEM for triplicate determinations except for IL-10, where data
are from single determinations.
(B) Forward by side scatter plots for SHIP+/+ (top) and −/− (bottom) PMΦs, selected as per Cook et al. (2003), were intracellularly stained with
isotype control (red) or 1/25 anti-Ym1 (blue) using a fix and perm kit (Caltag Lab, Burlingame, CA).
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(C) SHIP+/+ (solid squares) and −/− (open squares) PMΦ arginase activity was recorded as a function of mouse age (***p < 0.001 using
unpaired t test with Welch’s correction).
(D) LPS (100 ng/ml) + IFNγ (100 U/ml)-induced NO production is compared between PMΦs from 10-week-old (left) and 4-week-old (right)
SHIP+/+ (black bars) and −/− (gray bars) mice. Data shown are the mean ± SEM of triplicate determinations and similar results were obtained
in three separate experiments.
(E) TCLs from 2.5 × 105 SHIP+/+ and −/− PMΦs from 7- to 10-week-old and 4-week-old mice were treated for 3 hr ± 100 ng/ml LPS and
subjected to Western analysis for SHIP, phospho-p65 NF-κB (S536), pAkt (T308), Ym1, ArgI, and GAPDH.
levels (Figure 5A). This was consistent with our findingously injected Lewis lung tumors, ArgI was only ex-
pressed in the infiltrating mature macrophages (Rodri-
guez et al., 2004). Since levels of the M-CSF receptor,
c-fms, were equivalent in tumors of both genotypes
(Figure 3F), this suggested that enhanced Arg1 levels
in SHIP−/− tumors were not simply due to greater num-
bers of recruited MΦs.
Lastly, consistent with high in vivo arginase activity,
SHIP−/− mice displayed reduced plasma L-arginine
levels (Figure S2).
Further Characterization of the SHIP−/− M
Phenotype and Its Dependence on Mouse Age
To this point, we had characterized SHIP−/− MΦs as M2
based solely on their possessing elevated ArgI and
Ym1 and yielding low levels of NO in response to LPS.
However, M2 MΦs have been reported to be very
heterogeneous (Gordon, 2003; Mantovani et al., 2004)
and so to further characterize SHIP−/− MΦs, we investi-
gated other markers associated with an M2 phenotype.
Our results suggest that while SHIP+/+ and −/− 10-
week-old PMΦs express similar cell-surface levels of
scavenger receptor A (SR-A) (Figure S3B), Mac1 (CD11b),
c-fms, F4/80, and no Gr-1 (data not shown), the SHIP−/−
PMΦs constitutively express higher than normal levels
of Arg1, Ym1, IL-1Ra, IL-10, IL-6, TGFβ, and mannose
receptor and, in response to LPS, higher than normal
levels of IL-1Ra, IL-10, and TGFβ but lower levels of
TNFα, IL-6, IL-12, CCL3, and NO (Figure 4A, Figures
S3 and S5, and data not shown). These findings are
consistent with SHIP−/− PMΦs possessing an M2 MΦ
phenotype (Mantovani et al., 2004).
We then asked what proportion of PMΦs in SHIP−/−
mice display this M2 phenotype, since our Western and
ELISA data could not discriminate between a small pro-
portion of cells expressing very high levels of M2 pro-
teins or a large proportion expressing moderately ele-
vated M2 proteins. To do this, we compared FACS
profiles of PMΦs using our Ym1 antibody. As shown in
Figure 4B, we found that about 50% of the SHIP−/−
PMΦs, but none of the wild-type PMΦs, expressed
markedly elevated Ym1 levels.
We next examined the stability of the SHIP−/− PMΦ
M2 phenotype by incubating these cells ex vivo for 5
days ± M-CSF, IL-12, IFNγ, TNFα, or a media change
on day 2 and comparing ArgI, Ym1, and LPS-induced
NO levels. As shown in Figure S4A, SHIP−/− PMΦ ArgI
expression was relatively stable during the 5 days of in
vitro culture unless the medium was changed (), sug-
gesting, perhaps, that an autocrine mechanism was in-
volved in the maintenance of high Arg1. As well, LPS-
induced NO production remained undetectable under
all in vitro conditions (data not shown). In contrast, in-while SHIP−/− PMΦ ArgI expression and low NO pro-
duction is stable ex vivo, the signals required to sustain
high Ym1 expression may be present only in vivo. On
the other hand, we found that the addition of the TH2
cytokines, IL-4 and IL-13, induced the expression of
ArgI and Ym1 in SHIP+/+ PMΦs and maintained/induced
them in SHIP−/− PMΦs (Figure S4B).
Using 6- to 10-week-old mice, we found considerable
variability in SHIP−/− PMΦ ArgI levels, and a retrospec-
tive analysis suggested that PMΦs from older SHIP−/−
mice possessed higher ArgI levels. To corroborate this,
we examined the arginase activity in PMΦs from SHIP+/+
and −/− mice at different ages. We found PMΦs from
3- to 4-week-old SHIP−/− mice possessed, on average,
only 1.5-fold more arginase activity than in PMΦs from
SHIP+/+ mice. However, as the SHIP−/− mice aged, the
arginase activity increased dramatically in their PMΦs
(on average 3-fold and 12-fold over SHIP+/+ PMΦs at 5
weeks and 7–10 weeks, respectively) (Figure 4C). This
age-induced ArgI increase in SHIP−/− mice correlated
nicely with a reduced ability to produce NO in response
to LPS + IFNγ (Figure 4D). Similarly, Ym1 protein levels
were relatively normal in PMΦs from 4-week-old SHIP−/−
mice but were markedly elevated in PMΦs from 7- to
10-week-old SHIP−/− mice (Figure 4E).
We next compared LPS-induced signaling events in
SHIP+/+ and −/− PMΦs and found, similar to our previ-
ous results with BMMΦs (Sly et al., 2004), that the ab-
sence of SHIP resulted in an enhanced LPS-induced
phosphorylation of Akt (Figure 4E) (but not of Stat1 or
p38 [data not shown]) in PMΦs from both young and
old mice. In young SHIP−/−mice, where M1 cytokine
production was not dramatically impaired (Figure S5),
LPS-induced phosphorylation of p65 NF-κB (in the
transcriptional activation domain) was indistinguish-
able from wild-type (Figure 4E). However, LPS-induced
p65 phosphorylation was reduced in SHIP−/− PMΦs
from adult mice, and this may be related to their more
severe M1 impairment. Taken together, these results
implicate SHIP in LPS-induced signaling in PMΦs and
reveal that the M2 phenotype of SHIP−/− PMΦs is asso-
ciated with an enhanced ability to activate the PI3K/
PIP3/Akt pathway.
Mouse Plasma Skews the In Vitro Differentiation
of SHIP−/− Progenitors toward M2 BMMs
Having established that in vivo derived SHIP−/− PMΦs
and AMΦs possessed an M2 phenotype, we asked
whether MΦs derived from the bone marrow of SHIP−/−
mice under standard in vitro culture conditions (i.e.,
M-CSF + 10% FCS) were also M2 skewed, and we
found that this was not the case, i.e., SHIP−/− BMMΦs,
like SHIP+/+ BMMΦs, possessed undetectable ArgI
Immunity
368Figure 5. Mouse Plasma Skews the In Vitro Differentiation of SHIP−/− Myelomonocytic Progenitors toward M2 BMMΦs
(A) TCLs (2.5 g) from SHIP+/+ and −/− BMMΦs and PMΦs were subjected to Western analysis using anti-ArgI and anti-Grb2.
(B) SHIP−/− BMMΦs, generated after 7 days in IMDM + 10% FCS + 5 ng/ml M-CSF (−), + 10% supplemental FCS (FCS), or + 10% +MP (MP),
were subjected to ArgI and GAPDH Western analysis.
(C) In the left panel, SHIP−/− and +/+ bone marrow progenitors were cultured for 7 days in standard differentiation medium ± supplemental
FCS, +MP, −MP added 1 day after the initiation of the cultures (i.e., day 1). After 7 days, adherent cells with MΦ morphology were subjected
to ArgI and c-fms (loading control and MΦ differentiation marker) Western analysis. In the right panel, TCLs from (B) were subjected to an
arginase assay.
(D) SHIP−/− bone marrow progenitors were cultured as in (B) ± 5% FCS or 5% +MP, added on days 0, 1, 2, or 3, and lysates were assayed for
arginase activity as in (C).
(E) SHIP−/− bone marrow progenitors were treated as in (D) except that the day 1 addition of 5% +MP was preceded by a 30 min preincubation
with one dose of DMSO, wortmannin, or LY294002, which remained in the medium for the 7 day culture period. Results shown are the mean ±
SEM of duplicate determinations. Results are representative of three independent experiments.that LPS-induced NO production from SHIP−/− BMMΦs
was not impaired (Figure 1A) and that L-arginine sup-
plementation did not enhance it (Figure 1D).
In an attempt to mimic the in vivo differentiation envi-
r
(
f
conment in SHIP−/− mice, we added 10% mouse plasma
MP) to SHIP−/− in vitro bone marrow cultures and
ound, after 7 days of culture, that this dramatically in-
reased ArgI expression (Figure 5B). Supplementation
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effect. We then compared the effect of MP on the in
vitro differentiation of SHIP+/+ and −/− bone marrow cul-
tures and found that 2% SHIP+/+MP (+MP) or SHIP−/−
MP (−MP) dramatically increased ArgI levels (Figure 5C,
left) and activity (Figure 5C, right) in the fully developed
SHIP−/− BMMΦs, but not +/+ BMMΦs. Additionally, the
addition of MP during the in vitro differentiation of
SHIP−/− BMMΦs increased the expression of Ym1,
TGFβ, and IL-10 and led to a reduced synthesis of M1
markers (TNFα, CCL3, and NO) in response to LPS
(data not shown). Thus, the addition of MP successfully
mimicked in vivo MΦ differentiation in SHIP+/+ and −/−
mice and suggested that the in vivo skewing of SHIP−/−
MΦs requires both intrinsically elevated PIP3 levels and
an extracellular factor(s) present in the plasma of both
genotypes.
To gain some insight into when during differentiation
this plasma factor(s) acted, we carried out delayed ad-
dition studies with +MP and found that it was no longer
capable of inducing high arginase and Ym1 in SHIP−/−
BMMΦs if addition was delayed until day 2 (Figure 5D
and data not shown). This suggested that it was acting
early during MΦ differentiation. Moreover, inclusion of
the PI3K inhibitors, wortmannin, or LY294002 with +MP
in the 7 day assay diminished arginase induction, sug-
gesting that the plasma factor(s) was dependent upon
PI3K for M2 skewing (Figure 5E). Consistent with these
in vitro results suggesting that progenitors can become
M2 programmed in vivo, we found elevated arginase
activity (Figure S6A) and ArgI (Figure S6B) in peripheral
blood monocytes from SHIP−/− mice.
To identify the factor(s) in MP responsible for the
upregulation of ArgI in SHIP−/− MΦ progenitors, we
carried out dose-response studies with a number of
TH2-secreted cytokines. Although IL-4, and to a lesser
degree, IL-13, were potent inducers of ArgI, they in-
creased ArgI to the same degree in the resulting SHIP+/+
and −/− BMMΦs (Figure 6A). Nonetheless, since wort-
mannin and LY294002 dampened ArgI induction by IL-4
in both genotypes, this suggested that the process was
still PI3K dependent (Figure S7). IL-6 and GM-CSF, on
the other hand, had no effect alone on either cell type
(data not shown). Interestingly, TGFβ and IL-10 only in-
duced ArgI in the resulting SHIP−/− BMMΦs, making
them potential candidates for the MP factor (Figure 6A).
We therefore preincubated +MP with biotinylated anti-
TGFβ1 or biotinylated anti-IL-10, prebound to streptavi-
din beads, and incubated the depleted plasma samples
with SHIP−/− progenitors. As shown in Figure 6B, while
this depletion protocol effectively reduced the ability of
both exogenously added TGFβ1 and IL-10 to induce
arginase activity in the resulting BMMΦs, only TGFβ1
depletion of MP resulted in a reduction (50%) of argi-
nase activity. Thus, TGFβ1 in plasma is at least partially
responsible for ArgI induction in SHIP−/− MΦs. Since
−MP was about twice as potent as +MP in ArgI induc-
tion, we asked whether TGFβ levels were elevated in
the plasma of SHIP−/− mice, but this was not the case.
In fact, TFGβ levels (both total [Figure 6C] and active
[data not shown]) were consistently lower in SHIP−/−
plasma (Figure 6C). The levels of IL-4, IL-10, IL-12, and
IFNγ, on the other hand, were similar in SHIP+/+ and −/−
mouse plasma and present at very low levels (data notshown). However, SHIP−/− plasma did contain higher
IL-6 (Figure 6C) and TNFα (75 pg/ml versus 20 pg/ml in
pooled SHIP+/+ plasma via cytometric bead array)
levels, and it is possible one or both are involved.
Returning to IL-4 and IL-13, which induced arginase
equally well in SHIP+/+ and −/− bone marrow cultures
(Figure 6A), we found that IL-4 (and IL-13, data not
shown) could also induce ArgI in fully mature MΦs (Fig-
ure 6D), in keeping with previously published results
(Munder et al., 1999; Pauleau et al., 2004), while TGFβ
(Jost et al., 2003) or MP could not. We also found, by
removing IL-4, IL-13 (data not shown), or MP at dif-
ferent times during the 7 day culture period, that they
were all capable of skewing progenitors toward high
arginase-expressing mature BMMΦs to some extent,
even if they were only present during the first 2 days of
culture (Figure 6E). Thus, IL-4 and IL-13 appear capable
of M2 skewing both progenitors and mature macro-
phages.
Discussion
Currently, there is a great deal of controversy concern-
ing the time that M1 and M2 MΦs arise during differenti-
ation and the degree to which these cells can switch
phenotypes (Gordon, 2003; Ravasi et al., 2002; Stout
and Suttles, 2004). In order to harness these M1 and
M2 MΦs for future anticancer and anti-inflammatory
therapies, it is very important to resolve these issues.
The studies presented herein with SHIP−/− mice provide
some unexpected insights into the mechanisms that
govern MΦ programming. Specifically, our finding that
in vivo derived PMΦs and AMΦs from SHIP−/− mice are
M2 programmed while these same cells from SHIP+/+
mice have an M1 propensity suggests that SHIP plays
a key role in preventing M2 skewing. Additionally, our
finding that in vitro derived BMMΦs from SHIP−/− mice
are M1 skewed unless exposed to MP during differenti-
ation suggests that extracellular factors play an impor-
tant role in M1 versus M2 MΦ decisions.
Taken together, our data suggest a model in which
elevated PIP3 levels predispose MΦ progenitors toward
an M2 phenotype and SHIP acts as a potent negative
regulator of this skewing. In support of this, we found
that PI3K inhibitors prevented the induction of ArgI in
SHIP−/− MΦ progenitors by MP (Figure 5E) or TGFβ
(data not shown). We also propose that TGFβ and IL-10
can only skew SHIP−/− progenitors to an M2 phenotype
because they are weak PI3K-inducers (Bhattacharyya
et al., 2004; Kim et al., 2004) and are not known to acti-
vate Stat6. In fact, there is growing evidence that, at
least in some cell types, TGFβ and IL-10 may actually
antagonize the PI3K pathway (Kim et al., 2004; Remy
et al., 2004; Sly et al., 2004; Valderrama-Carvajal et al.,
2002).
On the other hand, since IL-4 and IL-13 could skew
both SHIP+/+ and −/− mature MΦs as well as their pro-
genitors toward an M2 phenotype, we propose they
can do so because they are not only robust activators
of the PI3K pathway (Kelly-Welch et al., 2003; Montaner
et al., 1999; Ruetten and Thiemermann 1997) but can
activate Stat6 as well (Kelly-Welch et al., 2003; Pauleau
et al., 2004). Related to this, we found that PI3K inhibi-
Immunity
370Figure 6. TGFβ and MP Induce ArgI in Differentiating SHIP−/− BMMΦs
(A) Bone marrow progenitors from SHIP+/+ and −/− mice were exposed to TH2 cytokines at the indicated doses (ng/ml), and arginase activity
was measured on day 7.
(B) 50 g of biotinylated neutralizing chicken anti-mouse TGFβ1 or goat anti-mouse IL-10, at 0.2 mg/ml in PBS, was conjugated to 300 l SA
beads. After washing in PBS to remove unbound antibody, 300 l aliquots of 5% +MP, 2.5 ng/ml TGFβ1, or 20 ng/ml IL-10 were incubated
for 1 hr at 4°C with 100 l of SA beads alone or antibody-conjugated beads. Suspensions were pulse-centrifuged and the supernatants
added to SHIP−/− bone marrow progenitors on day 1. Arginase assays were performed on day 7 as in (A).
(C) Plasma samples from 6- to 10-week-old SHIP+/+ and −/− mice were analyzed for TGFβ and IL-6 levels by ELISA.
(D) Bone marrow progenitors (Dev) or mature BMMΦs (Mat) from SHIP+/+ and SHIP−/− mice were treated ± 5% +MP or IL-4 (10 ng/ml) for 7
days (Dev) or 3 days (Mat), and arginase activity was determined.
(E) Bone marrow progenitors from SHIP+/+ (left) and −/− (right) mice were treated with IL-4 (10 ng/ml) and 5% +MP, respectively, on day 0,
and sham washed on day 2, or washed twice and replaced with non-IL-4 or non+MP-containing medium on day 2 or day 4. Arginase assays
were performed on day 7. Shown are the means ± SEM of duplicate determinations, and similar results were obtained in two independent ex-
periments.tors blocked IL-4- and IL-13-induced ArgI and Ym1 in
mature wild-type BMMΦs, without having any signifi-
cant effect on Stat6 phosphorylation (Figure S8 and
data not shown). This suggests that PI3K activation
may be a universal requirement for M2 programming,
and this may help to explain some of the controversy
surrounding the role of PI3K in TLR4 signaling. Thus,
although we and others (Rhee et al., 2003; Weinstein
et al., 2000) have shown that PI3K can stimulate LPS-
induced TLR4 signaling under some circumstances, it
also subsequently enhances an anti-inflammatory re-
sponse.
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trinsic PIP3 levels and TGFβ levels play the dominant
role.
With regard to the shift to a more pronounced M2
phenotype with age, previous studies with SHIP−/− mice
have shown that natural killer (NK) cells become more
tolerant as these mice age, and this prevents them from
rejecting mismatched bone marrow grafts (Wang et al.,
2002). Moreover, Coggeshall’s group recently showed
that IL-6 production by SHIP−/− myeloid cells leads to
an age-dependent suppression of early B cell develop-
ment in the bone marrow (Nakamura et al., 2004). Thus,
the SHIP−/− mouse may become more tolerant with age
and this may be an attempt to counter an environment
of chronic inflammation in these mice (Nathan, 2002).
This may explain the variability in LPS-induced iNOS
levels we observed in SHIP−/− PMΦs, since the lowest
levels were observed with cells from the oldest SHIP−/−
mice. This is consistent with reports suggesting that
the translation of iNOS may be negatively regulated by
ArgI-mediated L-arginine depletion and/or polyamine
production (Bussiere et al., 2005; El Gayar et al., 2003;
Lee et al., 2003). Related to this, both the PI3K pathway
and M2 MΦs have been implicated in the compensa-
tory anti-inflammatory response (CARS) (Bone, 1996)
observed in septic patients (Learn et al., 2001; Williams
et al., 2004), in noninfectious systemic inflammatory re-
sponse syndrome (SIRS), and in the susceptibility of
hosts to nosocomial infections (Adib-Conquy et al.,
2003; Takahashi et al., 2004).
One in vivo consequence of enhanced M2 MΦ pro-
gramming is likely the presence of fibrosis and Ym1
crystals in the lungs of SHIP−/− mice. Ym1 is a chi-
tinase-like secretory lectin that spontaneously crystal-
lizes under high concentrations (e.g., in chronic TH2-
type inflammation like asthma or parasitic infections),
particularly in the lung, is associated with the presence
of M2 MΦs (Nair et al., 2003; Raes et al., 2002; Welch
et al., 2002) and has been postulated to function in my-
elopoiesis (Hung et al., 2002) and allergic lung remodel-
ing (Hung et al., 2002; Webb et al., 2001). Interestingly,
Ym1 lung crystals have also been isolated from MeV
mice (Guo et al., 2000), which share many phenotypic
characteristics with SHIP−/− mice (Shultz et al., 1993;
Tsui et al., 1993), including chronic lung inflammation
(Helgason et al., 1998; Ward, 1978). These crystals may
represent an exaggerated manifestation of immune tol-
erance and healing and may, in fact, contribute to the
lung pathology in both mouse types. Taken together,
our results suggest that MΦs within SHIP−/−, and per-
haps MeV, mice become constitutively M2 programmed
and that this contributes to their lung pathology and
shortened life span.
In summary, while most studies on MΦ programming
thus far have been conducted with naive, in vitro dif-
ferentiated, mature BMMΦs, our studies with SHIP−/−
progenitors have revealed that the combination of in-
trinsic (i.e., elevated PIP3 levels) and extrinsic (i.e., cy-
tokine environment) factors during MΦ differentiation
can determine the MΦ phenotype. Naive, mature MΦs
can be M2 skewed by factors such as IL-4 and IL-13,
and this suggests that the MΦ phenotype can arise
both during differentiation and once it is completed. Im-
portantly, our studies have also revealed the require-ment for the PI3K pathway during M2 MΦ differentia-
tion and mature activation. Although our studies do not
distinguish between distinct M1 and M2 progenitors or
a plastic common progenitor, this in vitro system may
more accurately reflect the conditions of in vivo MΦ
differentiation and programming and be amenable to
future studies. Importantly, our studies caution against
extrapolating findings obtained with in vitro derived
BMMΦs to more complex and dynamic in vivo systems.
Finally, we suggest that targeting the SHIP/PI3K axis in
situ, or ex vivo, may represent a viable future means of
harnessing and manipulating the macrophage pheno-
type for cancer, infection, and chronic inflammation
therapies.
Experimental Procedures
LPS, Cytokines, Reagents, and Antibodies
E. coli LPS from serotype O127:B8 was from the Sigma Chemical
Company (St. Louis, MO). The cytokines IFNγ, IL-4, IL-6, IL-10, IL-
13, TGFβ1, GM-CSF, and M-CSF were from StemCell Technologies
(Vancouver, BC, Canada). The PI3K inhibitors LY294002 and wort-
mannin were from Calbiochem (La Jolla, CA), while L-nor-NOHA
and L-nor-valine were from Alexis Biochem (USA) and Sigma, re-
spectively. The following polyclonal rabbit antibodies were used:
iNOS, IκBα, Grb2, and c-fms (Santa Cruz), ERK1 (Stressgen),
pStat6, pp65 (S536), pAkt (T308) (Cell Signaling), SHIP (Damen et
al., 1998), and Ym1 (generated and affinity purified using the pep-
tide sequence GYTGENSPLYK). Mouse monoclonal antibodies
were used to detect ArgI (BD Transduction) and GAPDH (Research
Diagnostics). Biotinylated neutralizing chicken anti-mouse TGFβ1
and goat anti-mouse IL-10 were from R&D Systems, and 50 g of
each, reconstituted at 0.2 mg/ml in PBS, were conjugated to 300
l streptavidin-agarose (SA) beads (Pierce) according to the manu-
facturer’s instructions.
Tissue Culture
BMMΦs and PMΦs were obtained from SHIP+/+ and SHIP−/− mice
as described previously (Sly et al., 2004). For AMΦs, 0.8 ml pre-
warmed PBS was injected into the lungs of euthanized mice via the
trachea with a 22G needle and a 1 ml syringe (Becton Dickson) and
retrieved as BALF. The collected BALF (2–3 washes) was centri-
fuged at 300 × g and the cells resuspended with 1–2 ml of PMΦ
medium and plated in 12-well plates. AMΦs were selected by ad-
herence after repeated washings. For in vitro experiments to mimic
the in vivo environment of MΦ differentiation, bone marrow progen-
itor cells were cultured for 7 days in BMMΦ medium, without me-
dium change, at 0.5–2.0 × 106 cells/ml in 24-well plates ± cytokines
or MP.
Nitric Oxide Assay
NO production was determined indirectly by measuring the accu-
mulation of the stable end product, NO2−, in the tissue culture su-
pernatant using the Griess reaction, as described previously (Sly et
al., 2004).
Arginase Assay
Arginase activity was assessed indirectly by measuring the con-
centration of urea generated by the arginase-dependent hydrolysis
of L-arginine, as described (Morrison and Correll, 2002).
ELISAs
Tissue culture supernatants of resting or stimulated MΦs were as-
sessed for protein levels of TNFα, IL-6, CCL3, IL-10, and IL-12 by
ELISA (BD Biosciences, Mississauga, ON, Canada) according to
the manufacturer’s instructions. For mouse plasma analysis, a
FACS-based cytometric bead array IL-6, IL-10, IL-12, TNFα, IFNγ,
and CCL2/MCP-1 Mouse Inflammation ELISA kit (BD Biosciences)
was used according to the manufacturer’s instructions. Latent +
active TGFβ was assessed in mouse plasma and supernatants by
Immunity
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FCS subtracted.
Cell Lysis and Western Analysis
MΦs were either lysed directly into 1×SDS sample buffer or into
arginase assay buffer. For the latter, protein levels were determined
by Bradford assay and samples supplemented with concentrated
SDS sample buffer to give 1×SDS sample buffer. All samples were
then boiled for 5 min and subjected to Western analysis as de-
scribed previously (Sly et al., 2004).
Lung Crystal Isolation and Mass Spectroscopy Analysis
Crystals were purified from the lungs of SHIP−/− mice as previously
described for MeV mice (Guo et al., 2000), boiled for 5 min in
1×SDS sample buffer, and subjected to SDS-PAGE, along with cell-
free BALF from SHIP+/+ and −/− mice. The purified 45 kDa band
was excised and subjected to in-gel trypsin digestion and subse-
quent MALDI-TOF MS and ESI MS/MS at the UBC Laboratory of
Molecular Biophysics Proteomics Core Facility (Vancouver, BC,
Canada).
Lung Histology and BAL Analysis
Lungs were collected from SHIP+/+ and −/− mice, formalin fixed,
ethanol washed, and paraffin embedded. Lung sections were ob-
tained and stained with MSB or H&E, using standard techniques.
Photomicrographs of stained histological sections or BALF and
cells were obtained using a QImaging QICAM Fast 1394 Cooled
Color 12-bit digit camera mounted on a Leica DMIL microscope, at
200× or 400× original magnification.
RNA Preparation, RPA, and RT-PCR
RNA was isolated as described previously (Sly et al., 2004). RPA of
cytokine mRNA levels was performed on 2–10 g of total RNA
using the RiboquantTM Multi-Probe RPA (BD Pharmingen) and
template sets mCK2 as described previously (Kalesnikoff et al.,
2002). PCR reactions were carried out using previously described
primers and conditions specific for ArgI and β-actin (Morrison and
Correll, 2002) and Ym1 (Nair et al., 2003), but cycle numbers were
optimized for our own laboratory. Negative controls were minus
reverse transcriptase and minus template. Black-white inverted
images of PCR bands were obtained using a Kodak Digital Science
DC40 Camera mounted to a Fisher Biotechnology Transilluminator.
Transient Transfections
SHIP+/+ PMΦs were seeded at 2 × 106 cells/6 cm plate and
transiently transfected using DEAE-Dextran. In brief, 0, 2.5, or
5 g of a vector containing constitutively active PI3K (pSG5-mycT-
p110αCAAX from Drs. J. Downward and S. Wennstrom [Jimenez et
al., 1998]) was incubated with DEAE-dextran, at 0.5 mg/ml, in 3 ml
IMDM-0.5×PBS for 15 min at 23°C. After two cell washes in IMDM,
the DNA/DEAE-dextran mixture was added for 15 min at 23°C. After
aspiration, cells were washed once with IMDM and placed in PMΦ
medium overnight. The following day, cells were lysed for arginase
assays and Western analyses as described above.
Murine Tumor Model
6- to 10-week-old SHIP+/+ and −/− mice were subcutaneously in-
jected with 2 × 105 M27 Lewis lung carcinoma cells and tumor
volume (mm3) determined over time using calipers and the formula
for volume of an ellipsoid. Tumors were also harvested from several
mice at day 17 and minced into tiny pieces with scissors, and pro-
tein lysates were prepared by homogenizing the tissue in 0.5% NP-
40 detergent in PSB plus protease inhibitors, using a syringe and
progressively higher gauge needles (Damen et al., 1998). Equivalent
protein amounts were then subjected to Western blot analysis for
ArgI, c-fms, and GAPDH.
Statistical Analysis
Unpaired, two-tailed Student’s t tests were performed where indi-
cated, using GraphPad Prism version 3.02 (GraphPad Software In-
corporated).
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